Wire Stories

VicTrack Rides With Juniper Networks on Network Refresh Journey to Fuel Business Growth

Juniper-powered solutions enable VicTrack to build on its wide transportation network to provide leading communications solutions to customers across its…

5 years ago

BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting

Scheduled to present results and trial designs on five therapeutic candidates from 13 clinical trials across eight types of cancer…

5 years ago

Aumolertinib Significantly Prolongs Progression-Free Survival with Fewer Side Effects in the First-Line Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Results of the Phase III AENEAS trial, to be presented at ASCO 2021, demonstrate better efficacy and improved tolerability, including…

5 years ago

KE Holdings Inc. Announces First Quarter 2021 Unaudited Financial Results

BEIJING--(BUSINESS WIRE)--KE Holdings Inc. (“Beike” or the “Company”) (NYSE: BEKE), a leading integrated online and offline platform for housing transactions…

5 years ago

Digi Relocates Australian Headquarters to Milton to Bolster Exponential Growth and Opportunities

Newly renovated facility in Milton will drive collaboration, and engineering leadership to re-affirm market-leading position as employees return to office…

5 years ago

Labcorp to Expand Bioanalytical Services With Integrated Laboratory in Singapore

New Laboratory Grows Asia-Pacific Operations BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced the expansion…

5 years ago

Takeda to Present Positive Primary Analysis from Phase 2 OPTIC Trial of ICLUSIG® (ponatinib), Reinforcing Ability to Address Gaps in Care for Chronic-Phase CML

– OPTIC Trial Evaluating Response-Based Dosing Regimens of ICLUSIG for the Treatment of Resistant / Intolerant Chronic-Phase CML Demonstrates Durable,…

5 years ago

Takeda Presents Updated Results for Mobocertinib, Further Substantiating the Clinical Benefit in Patients with EGFR Exon20 Insertion+ mNSCLC

? Mobocertinib, an Oral Targeted Therapy, Demonstrated a Median Overall Survival of 24 Months, and Responses were Observed across Diverse…

5 years ago

Sugarbud Announces Second Consecutive Positive EBITDA Result for Q1 2021, Filing of First Quarter Financial Results and Corporate Update

CALGARY, Alberta, May 19, 2021 (GLOBE NEWSWIRE) -- Sugarbud Craft Growers Corp. (TSXV: SUGR, SUGR.DB, SUGR.WR, SUGR.WS, SUGR.WT) (OTCQB: SBUDF)…

5 years ago